{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:48:57Z","timestamp":1790354937914,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["40011958"],"award-info":[{"award-number":["40011958"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.beem.2026.102085","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T08:01:40Z","timestamp":1770710500000},"page":"102085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dopamine agonist withdrawal in patients with prolactinoma"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2665-9455","authenticated-orcid":false,"given":"Stefan Matei","family":"Constantinescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orsalia","family":"Alexopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Maiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.beem.2026.102085_bib1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1210\/endo-54-6-685","article-title":"Luteotrophic function of autografts of the rat hypophysis","volume":"54","author":"Everett","year":"1954","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2026.102085_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1152\/ajplegacy.1963.205.2.213","article-title":"In vitro inhibition of pituitary prolactin synthesis and release by hypothalamic extract","volume":"205","author":"Talwalker","year":"1963","journal-title":"Am J Physiol"},{"issue":"4","key":"10.1016\/j.beem.2026.102085_bib3","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1210\/endo-94-4-1077","article-title":"Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion","volume":"94","author":"MacLeod","year":"1974","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.beem.2026.102085_bib4","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1210\/jcem-51-3-438","article-title":"Rapid regression of pituitary prolactinomas during bromocriptine treatment","volume":"51","author":"Thorner","year":"1980","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"10.1016\/j.beem.2026.102085_bib5","first-page":"904","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea","volume":"331","author":"Webster","year":"1994","journal-title":"Cabergoline Comp Study Group N Engl J Med"},{"issue":"7","key":"10.1016\/j.beem.2026.102085_bib6","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients","volume":"84","author":"Verhelst","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2026.102085_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2026.102085_bib8","series-title":"The Pituitary Fifth ed","first-page":"495","article-title":"Prolactinoma","author":"Chanson","year":"2022"},{"issue":"8","key":"10.1016\/j.beem.2026.102085_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2023.102910","article-title":"Impulse control disorders in patients with pituitary tumors treated with dopamine agonists: a systematic review","volume":"54","author":"Hamblin","year":"2023","journal-title":"Arch Med Res"},{"issue":"3","key":"10.1016\/j.beem.2026.102085_bib10","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz076","article-title":"Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors","volume":"105","author":"De Sousa","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.beem.2026.102085_bib11","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S2213-8587(14)70212-8","article-title":"The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data","volume":"3","author":"Caputo","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2026.102085_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1530\/EJE-07-0259","article-title":"Quality of life is decreased in female patients treated for microprolactinoma","volume":"157","author":"Kars","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2026.102085_bib13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11102-008-0091-9","article-title":"Quality of life in women with microprolactinoma treated with dopamine agonists","volume":"11","author":"Cesar de Oliveira Naliato","year":"2008","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.beem.2026.102085_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/EJE-18-0682","article-title":"Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas","volume":"180","author":"Ioachimescu","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2026.102085_bib15","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaf355","article-title":"Subtle cognitive impairments and psychological complaints in patients with prolactinoma despite biochemical control","author":"van Trigt","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.beem.2026.102085_bib16","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2026.102085_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11102-019-00989-1","article-title":"Dopamine agonists in prolactinomas: when to withdraw?","volume":"23","author":"Souteiro","year":"2020","journal-title":"Pituitary"},{"issue":"10","key":"10.1016\/j.beem.2026.102085_bib18","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S2213-8587(25)00227-X","article-title":"Prolactin-secreting adenomas: pathogenesis, diagnosis, and management","volume":"13","author":"Fleseriu","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"20","key":"10.1016\/j.beem.2026.102085_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011247","article-title":"Molecular pathways in prolactinomas: translational and therapeutic implications","volume":"22","author":"Biagetti","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"20","key":"10.1016\/j.beem.2026.102085_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14207344","article-title":"Immunohistochemical comparison of dopamine-2 receptor expression in resistant and non-resistant prolactinomas","volume":"14","author":"Ramer Bass","year":"2025","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.beem.2026.102085_bib21","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/ejendo\/lvaf196","article-title":"Transcriptomic classification of prolactinomas and somatotropinomas identifies subtypes with variable resistance to treatment","volume":"193","author":"Bioletto","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2026.102085_bib22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1210\/jcem-63-2-383","article-title":"Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland","volume":"63","author":"Esiri","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2026.102085_bib23","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1210\/clinem\/dgad758","article-title":"Presurgical medical treatment in prolactinomas: surgical implications and pathological characteristics from 290 cases","volume":"109","author":"Chen","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2026.102085_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11102-025-01628-8","article-title":"Long-term cabergoline use does not predict degree of prolactinoma fibrosis nor significantly impact surgical outcomes","volume":"29","author":"Mamelak","year":"2026","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.beem.2026.102085_bib25","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1055\/s-0044-1791504","article-title":"Letter to the editor regarding \"the effect of preoperative cabergoline on prolactinoma fibrosis: a case series\"","volume":"85","author":"Acitores Cancela","year":"2024","journal-title":"J Neurol Surg Rep"},{"issue":"1","key":"10.1016\/j.beem.2026.102085_bib26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00401-005-1111-8","article-title":"Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists","volume":"111","author":"Kontogeorgos","year":"2006","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1016\/j.beem.2026.102085_bib27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4103\/ajns.AJNS_16_20","article-title":"Decrease of proliferative potential and vascular density of giant prolactinoma in patients treated with cabergoline","volume":"15","author":"Astaf'eva","year":"2020","journal-title":"Asian J Neurosurg"},{"issue":"3","key":"10.1016\/j.beem.2026.102085_bib28","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2265.2007.02905.x","article-title":"Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy","volume":"67","author":"Colao","year":"2007","journal-title":"Clin Endocrinol"},{"issue":"7","key":"10.1016\/j.beem.2026.102085_bib29","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1210\/jc.2008-2103","article-title":"Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy","volume":"94","author":"Kharlip","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2026.102085_bib30","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2265.2009.03657.x","article-title":"Factors determining the remission of microprolactinomas after dopamine agonist withdrawal","volume":"72","author":"Huda","year":"2010","journal-title":"Clin Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2026.102085_bib31","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2265.2011.04136.x","article-title":"Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma","volume":"75","author":"Barber","year":"2011","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2026.102085_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11102-011-0303-6","article-title":"Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience","volume":"15","author":"Anagnostis","year":"2012","journal-title":"Pituitary"},{"issue":"12","key":"10.1016\/j.beem.2026.102085_bib33","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s40618-016-0483-z","article-title":"Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas","volume":"39","author":"Sala","year":"2016","journal-title":"J Endocrinol Investig"},{"issue":"6","key":"10.1016\/j.beem.2026.102085_bib34","first-page":"440","article-title":"Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma","volume":"16","author":"Dogan","year":"2016","journal-title":"Anatol J Cardiol"},{"issue":"3","key":"10.1016\/j.beem.2026.102085_bib35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11102-016-0708-3","article-title":"Withdrawal of dopamine agonist therapy in prolactinomas: in which patients and when?","volume":"19","author":"Dogansen","year":"2016","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.beem.2026.102085_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/cen.13240","article-title":"Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal","volume":"86","author":"Watanabe","year":"2017","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2026.102085_bib37","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s11102-017-0820-z","article-title":"Best candidates for dopamine agonist withdrawal in patients with prolactinomas","volume":"20","author":"Ji","year":"2017","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.beem.2026.102085_bib38","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11102-017-0806-x","article-title":"Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal","volume":"20","author":"Teixeira","year":"2017","journal-title":"Pituitary"},{"issue":"2-3","key":"10.1016\/j.beem.2026.102085_bib39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12672-019-00363-4","article-title":"Cabergoline withdrawal before and after menopause: outcomes in microprolactinomas","volume":"10","author":"Indirli","year":"2019","journal-title":"Horm Cancer"},{"issue":"12","key":"10.1016\/j.beem.2026.102085_bib40","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa652","article-title":"Predictors of the response to dopaminergic therapy in patients with prolactinoma","volume":"105","author":"Hage","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2026.102085_bib41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12020-020-02388-0","article-title":"High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?","volume":"70","author":"Espinosa-Cardenas","year":"2020","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.beem.2026.102085_bib42","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1210\/clinem\/dgaa744","article-title":"Biochemical remission after cabergoline withdrawal in hyperprolactinemic patients with visible remnant pituitary adenoma","volume":"106","author":"Kim","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2026.102085_bib43","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s12020-025-04215-w","article-title":"Response to cabergoline treatment, gonadal axis recovery, and outcomes of drug withdrawal, in men with microprolactinoma: a retrospective cohort study","volume":"89","author":"Rudman","year":"2025","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.beem.2026.102085_bib44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","article-title":"Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis","volume":"95","author":"Dekkers","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2026.102085_bib45","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s11102-014-0617-2","article-title":"Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis","volume":"18","author":"Hu","year":"2015","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.beem.2026.102085_bib46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12020-017-1444-9","article-title":"Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis","volume":"59","author":"Xia","year":"2018","journal-title":"Endocrine"},{"issue":"12","key":"10.1016\/j.beem.2026.102085_bib47","doi-asserted-by":"crossref","first-page":"e1506","DOI":"10.1210\/clinem\/dgad393","article-title":"Long-term follow-up of 84 patients with giant prolactinomas-a swedish nationwide study","volume":"108","author":"Himonakos","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.beem.2026.102085_bib48","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaf152","article-title":"Menopause has a beneficial influence on the evolution of prolactinomas. A study of 99 patients","volume":"110","author":"Constantinescu","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2026.102085_bib49","doi-asserted-by":"crossref","first-page":"R55","DOI":"10.1093\/ejendo\/lvae120","article-title":"Diagnosis and management of pituitary adenomas in children and adolescents","volume":"191","author":"Maiter","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2026.102085_bib50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00431-017-3042-5","article-title":"Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis","volume":"177","author":"Hoffmann","year":"2018","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.beem.2026.102085_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2023.967407","article-title":"Prolactinomas in adolescent and elderly patients-a comparative long-term analysis","volume":"10","author":"Andereggen","year":"2023","journal-title":"Front Surg"},{"issue":"3","key":"10.1016\/j.beem.2026.102085_bib52","doi-asserted-by":"crossref","first-page":"269","DOI":"10.14744\/nci.2024.65049","article-title":"Clinical, hormonal and radiological features, and treatment outcomes of prolactinomas in a pediatric population","volume":"12","author":"Emeksiz","year":"2025","journal-title":"North Clin Istanb"},{"issue":"3","key":"10.1016\/j.beem.2026.102085_bib53","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000525226","article-title":"Outcome of dopamine agonist therapy withdrawal in children with prolactinomas","volume":"95","author":"Almutlaq","year":"2022","journal-title":"Horm Res Paediatr"},{"issue":"3","key":"10.1016\/j.beem.2026.102085_bib54","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/cen.14394","article-title":"Prolactinoma in childhood and adolescence-Tumour size at presentation predicts management strategy: Single centre series and a systematic review and meta-analysis","volume":"94","author":"Arya","year":"2021","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2026.102085_bib55","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1530\/EJE-10-0519","article-title":"Pituitary adenomas in childhood, adolescence and young adulthood: presentation, management, endocrine and metabolic outcomes","volume":"163","author":"Steele","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2026.102085_bib56","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3389\/fendo.2020.00527","article-title":"Clinical, hormonal, and neuroradiological characteristics and therapeutic outcomes of prolactinomas in children and adolescents at a single center","volume":"11","author":"Yang","year":"2020","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2026.102085_bib57","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41574-023-00949-7","article-title":"Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 2, specific diseases","volume":"20","author":"Korbonits","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2026.102085_bib58","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","article-title":"Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a pituitary society statement","volume":"20","author":"Casanueva","year":"2017","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.beem.2026.102085_bib59","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-21-0462","article-title":"ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy","volume":"185","author":"Luger","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2026.102085_bib60","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/cen.15304","article-title":"Safety of cabergoline for prolactinoma in pregnancy: a systematic review and meta-analysis","volume":"103","author":"Chakraborty","year":"2025","journal-title":"Clin Endocrinol"},{"issue":"9","key":"10.1016\/j.beem.2026.102085_bib61","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1210\/clinem\/dgad174","article-title":"Approach to the patient with prolactinoma","volume":"108","author":"Auriemma","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.beem.2026.102085_bib62","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/oxfordjournals.humrep.a137010","article-title":"Is pregnancy the best treatment for hyperprolactinaemia?","volume":"4","author":"Crosignani","year":"1989","journal-title":"Hum Reprod"},{"issue":"3","key":"10.1016\/j.beem.2026.102085_bib63","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0028-2243(92)90094-F","article-title":"Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women","volume":"44","author":"Crosignani","year":"1992","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"10.1016\/j.beem.2026.102085_bib64","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2265.1996.00824.x","article-title":"Long-term follow-up of patients with hyperprolactinaemia","volume":"45","author":"Jeffcoate","year":"1996","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2026.102085_bib65","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1210\/jc.2012-3039","article-title":"Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation","volume":"98","author":"Auriemma","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2026.102085_bib66","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12370","article-title":"Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients","volume":"80","author":"Domingue","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"10","key":"10.1016\/j.beem.2026.102085_bib67","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1055\/s-0043-112861","article-title":"Pregnancy and Tumor Outcomes in Women with Prolactinoma","volume":"125","author":"Araujo","year":"2017","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"10.1016\/j.beem.2026.102085_bib68","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/ajo.13070","article-title":"An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists","volume":"60","author":"O'Sullivan","year":"2020","journal-title":"Aust NZ J Obstet Gynaecol"},{"issue":"2","key":"10.1016\/j.beem.2026.102085_bib69","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11102-019-01008-z","article-title":"A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas","volume":"23","author":"Sant' Anna","year":"2020","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.beem.2026.102085_bib70","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11102-024-01384-1","article-title":"Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center","volume":"27","author":"Prencipe","year":"2024","journal-title":"Pituitary"},{"issue":"12","key":"10.1016\/j.beem.2026.102085_bib71","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.1073\/pnas.75.12.5946","article-title":"Estrogen control of prolactin synthesis in vitro","volume":"75","author":"Lieberman","year":"1978","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.beem.2026.102085_bib72","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF02899695","article-title":"Pituitary lactotrophs and somatotrophs in pregnancy: a correlative in situ hybridization and immunocytochemical study","volume":"62","author":"Stefaneanu","year":"1992","journal-title":"Virchows Archiv B Cell Pathol Includ Mol Pathol"},{"key":"10.1016\/j.beem.2026.102085_bib73","doi-asserted-by":"crossref","DOI":"10.1155\/ije\/8883536","article-title":"Effects of Ovariectomy and Sex Steroids on Prolactin Synthesis","volume":"2025","author":"Cairang","year":"2025","journal-title":"Int J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2026.102085_bib74","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/cen.13765","article-title":"Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal","volume":"89","author":"Santharam","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2026.102085_bib75","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12902-025-02105-w","article-title":"Management for prolactinomas of postmenopausal female patients: a retrospective single-center study","volume":"25","author":"Chen","year":"2025","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.beem.2026.102085_bib76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fendo.2015.00011","article-title":"Second attempt of cabergoline withdrawal in patients with prolactinomas after a failed first attempt: is it worthwhile?","volume":"6","author":"Vilar","year":"2015","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2026.102085_bib77","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11102-013-0525-x","article-title":"Second attempt to withdraw cabergoline in prolactinomas: a pilot study","volume":"17","author":"Kwancharoen","year":"2014","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.beem.2026.102085_bib78","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2265.2001.01190.x","article-title":"The effect of the menopause on prolactin levels in patients with hyperprolactinaemia","volume":"54","author":"Karunakaran","year":"2001","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2026.102085_bib79","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1590\/2359-3997000000138","article-title":"Prolactinomas: evolution after menopause","volume":"60","author":"Mallea-Gil","year":"2016","journal-title":"Arch Endocrinol Metab"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X26000060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X26000060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:20:46Z","timestamp":1788866446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X26000060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1521690X26000060"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2026.102085","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dopamine agonist withdrawal in patients with prolactinoma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2026.102085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102085"}}